Vanity Fair unpacks “psilocybin’s big week” which included both a groundbreaking study and votes for reform in Oregon and Washington D.C.
- Oregon voted to allow psilocybin therapy and Washington D.C. decriminalized the hallucinogen.
- A new study from Johns Hopkins found that two therapeutic doses of the drug may benefit patients with depression.
- “This is a new model in terms of psychiatry,” Roland Griffiths, Ph.D., the study’s lead researcher and a professor in the departments of psychiatry and neuroscience said. “Frankly, it looks more like an orthopedic surgical manipulation…You go in, you replace a hip and establish functioning, and you expect the person to be enduringly better, if it works.”
- Approximately 10% of the U.S. population has a diagnosis for major depression annually.
Canna Law Blog offers 10 lessons from the cannabis industry for the future regulated psychedelics industry.
